首页> 外文期刊>International Immunology >Role of Vα14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Vα14+ NKT cells promotes the breakage of CTL tolerance
【24h】

Role of Vα14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Vα14+ NKT cells promotes the breakage of CTL tolerance

机译:Vα14 + NKT细胞在乙型肝炎病毒特异性CTL发生中的作用:Vα14 + NKT细胞的激活促进CTL耐受性的破坏

获取原文
获取原文并翻译 | 示例
       

摘要

CTLs are thought to be major effectors for clearing viruses in acute infections including hepatitis B virus (HBV). Persistent HBV infection is characterized by a lack of or a weak CTL response to HBV, which is thought to reflect tolerance to HBV antigens. In the present study, we found that alpha-galactosylceramide (α-GalCer), a ligand for Vα14-positive NKT cells, strongly enhanced the induction and proliferation of HBV-specific CTLs by HBsAg. In HBsAg transgenic mice, which are thought to be tolerant to HBV-encoded antigens, administration of HBsAg or α-GalCer alone failed to induce HBsAg-specific CTLs, but they were induced by co-administration of both compounds. Furthermore, by limiting dilution analysis, we confirmed the existence of HBsAg-specific CTL precursors in the HBsAg transgenic mice immunized with HBsAg and α-GalCer. A blocking experiment using antibodies to cytokines and CD40 ligand showed that IL-2 and CD40–CD40L interaction mediate the enhancement of CTL induction caused by α-GalCer through NKT cell activation. Our results may open up a new method for clearing the virus from patients with persistent HBV infection.
机译:CTL被认为是清除包括乙型肝炎病毒(HBV)在内的急性感染中病毒的主要作用因子。持久性HBV感染的特征是对HBV缺乏或弱的CTL反应,这被认为反映了对HBV抗原的耐受性。在本研究中,我们发现Vα14阳性NKT细胞的配体α-半乳糖神经酰胺(α-GalCer)强烈增强了HBsAg对HBV特异性CTL的诱导和增殖。在被认为可以耐受HBV编码抗原的HBsAg转基因小鼠中,单独施用HBsAg或α-GalCer不能诱导HBsAg特异性CTL,但它们是由两种化合物共同施用诱导的。此外,通过有限稀释分析,我们确认了在用HBsAg和α-GalCer免疫的HBsAg转基因小鼠中存在HBsAg特异性CTL前体。使用针对细胞因子和CD40配体的抗体进行的封闭实验表明,IL-2和CD40–CD40L相互作用通过NKT细胞活化介导了由α-GalCer引起的CTL诱导增强。我们的结果可能为从持续性HBV感染患者中清除病毒提供了新方法。

著录项

  • 来源
    《International Immunology》 |2008年第7期|869-879|共11页
  • 作者单位

    Department of Informative Clinical Medicine Gifu University Graduate School of Medicine 1-1 Yanagido Gifu 501-1194 Japan;

    Department of Microbiology and Immunology Aichi Medical University Nagakute Aichi 480-1195 Japan;

    Goto Clinic Gifu 503-0899 Japan;

    Cancer Immunotherapy Center Nagoya Kyoritsu Hospital 1-172 Hokke Nakagawa Nagoya 454-0933 Japan;

    Department of Immunology Graduate School of Medicine Chiba University 1-8-1 Inohana Chuo-ku Chiba 260-8670 Japan;

    RIKEN Research Center for Allergy and Immunology RIKEN Yokohama Institute 1-7-22 Suehiro-cho Tsurumi-ku Yokohama City Kanagawa 230-0045 Japan;

    Human Health Sciences Graduate School of Medicine and Faculty of Medicine Kyoto University 53 Kawahara-cho Shogoin Sakyo Kyoto 606-8507 Japan;

    Second Department of Internal Medicine Showa University School of Medicine 1-5-8 Hatanodai Shinagawa-ku Tokyo 142-8666 Japan;

    First Department of Internal Medicine Gifu University Graduate School of Medicine 1-1 Yanagido Gifu 501-1194 Japan;

    Division of Gastroenterology Department of Internal Medicine Aichi Medical University Nagakute Aichi 480-1195 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号